Mesenchymal stem cells (MSCs) are multipotent cells with the ability to self-renew and differentiate into various cell types. They have been widely studied for their therapeutic potential in regenerative medicine. However, recent research suggests that the benefits of MSC therapy may be due to the bioactive factors they secrete rather than their engraftment and differentiation. Secretome-derived products, such as conditioned media or exosomes, offer advantages over living cells in terms of manufacturing, storage, handling, and shelf life. MSCs can be obtained from various sources, including bone marrow, adipose tissue, and the uterine cervix. Human uterine cervical stem cells (hUCESCs) are particularly promising due to their ease of isolation and high proliferative rate. The secretome from MSCs has been shown to have immunomodulatory, anti-inflammatory, anti-apoptotic, wound healing, neuroprotective, angiogenic, and antitumor effects. MSC-derived secretome can be used in various therapeutic applications, including tissue repair, wound healing, and the treatment of diseases such as cancer and neurodegenerative disorders. The use of MSC secretome-based therapies is gaining attention due to their potential as a ready-to-use biological product. However, regulatory requirements for manufacturing and quality control are necessary to ensure the safety and efficacy of these products. The secretome from MSCs has a complex composition, and its effects may vary depending on the source of the MSCs. Further research is needed to standardize the production and application of MSC secretome-based therapies.Mesenchymal stem cells (MSCs) are multipotent cells with the ability to self-renew and differentiate into various cell types. They have been widely studied for their therapeutic potential in regenerative medicine. However, recent research suggests that the benefits of MSC therapy may be due to the bioactive factors they secrete rather than their engraftment and differentiation. Secretome-derived products, such as conditioned media or exosomes, offer advantages over living cells in terms of manufacturing, storage, handling, and shelf life. MSCs can be obtained from various sources, including bone marrow, adipose tissue, and the uterine cervix. Human uterine cervical stem cells (hUCESCs) are particularly promising due to their ease of isolation and high proliferative rate. The secretome from MSCs has been shown to have immunomodulatory, anti-inflammatory, anti-apoptotic, wound healing, neuroprotective, angiogenic, and antitumor effects. MSC-derived secretome can be used in various therapeutic applications, including tissue repair, wound healing, and the treatment of diseases such as cancer and neurodegenerative disorders. The use of MSC secretome-based therapies is gaining attention due to their potential as a ready-to-use biological product. However, regulatory requirements for manufacturing and quality control are necessary to ensure the safety and efficacy of these products. The secretome from MSCs has a complex composition, and its effects may vary depending on the source of the MSCs. Further research is needed to standardize the production and application of MSC secretome-based therapies.